Skip to Content
Merck
CN
  • Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: a systematic review and network meta-analysis.

Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: a systematic review and network meta-analysis.

Joint, bone, spine : revue du rhumatisme (2014-01-07)
Glen S Hazlewood, Claudia Metzler, George A Tomlinson, Wolfgang L Gross, Brian M Feldman, Loic Guillevin, Christian Pagnoux
ABSTRACT

To determine the comparative efficacy of non-biologic treatments for remission maintenance in ANCA-associated vasculitis. We identified all randomized trials comparing leflunomide, azathioprine, methotrexate or mycophenolate mofetil in adult patients with granulomatosis with polyangiitis or microscopic polyangiitis. Relapse-free survival was compared through hazard ratios (HR) using a Bayesian fixed-effects network meta-analysis. Multiple sensitivity analyses were performed to explore biases identified in one trial using original trial data. Three trials were available (leflunomide-methotrexate, methotrexate- azathioprine, azathioprine-mycophenolate). Mycophenolate was inferior to all treatments, although the 95% credible interval (CrI) of the HR relative to methotrexate crossed 1. Leflunomide was superior to azathioprine (HR 0.43 [95% CrI: 0.14-1.3]) and methotrexate (HR 0.47 [95% CrI: 0.18-1.2]), although the 95% CrI also crossed 1. There was a 90% probability that leflunomide was the best treatment. After down weighting the effect of leflunomide vs. methotrexate for early trial termination and slow MTX dose escalation, there remained a 55% probability leflunomide was best. Based on indirect evidence, leflunomide is effective in maintaining remission in granulomatosis with polyangiitis or microscopic polyangiitis relative to other non-biologic treatments. Further randomized trials of leflunomide are needed for confirmation.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Azathioprine, ≥98%
Supelco
Mycophenolic acid solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Azathioprine, Pharmaceutical Secondary Standard; Certified Reference Material
Mycophenolate mofetil, European Pharmacopoeia (EP) Reference Standard
Azathioprine, European Pharmacopoeia (EP) Reference Standard
USP
Mycophenolate mofetil, United States Pharmacopeia (USP) Reference Standard
Leflunomide, European Pharmacopoeia (EP) Reference Standard
Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Leflunomide, Immunosuppressant
Supelco
Leflunomide, Pharmaceutical Secondary Standard; Certified Reference Material
Mycophenolate mofetil for peak identification, European Pharmacopoeia (EP) Reference Standard
USP
Leflunomide, United States Pharmacopeia (USP) Reference Standard